Farnesyltransferase inhibitors: Targeting the molecular basis of cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1423, Issue 3, 1999, Pages

  Oliff, Allen ^a  

^a Building 16 ^*  (United States)

Author keywords

Cancer; D rug; Farnesyltransferase; Geranylgeranyltransferase; Inhibitor; Oncogene; Ras; Therapy

Indexed keywords

DIMETHYLALLYLTRANSFERASE; FARNESYL TRANS TRANSFERASE; GERANYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RAT; REVIEW;

ANIMALIA;

EID: 0033620684     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(99)00007-4     Document Type: Article

References (63)

1. V. DeVita, S. Hellman and S. Rosenberg (Eds.), Cancer Principles and Practice of Oncology, 5th edn., Lippincott-Raven Press, Philadelphia, PA, 1997.
2. J.B. Gibbs, A. Oliff, Pharmaceutical research in molecular oncology, Cell 79 (1994) 193-198.
3. G. Bollag, F. McCormick, Regulators and effectors of ras proteins, Annu. Rev. Cell Biol. 7 (1991) 601-632.
4. D.R. Lowy, B.M. Willumsen, Function and regulation of ras, Ann. Rev. Biochem. 62 (1993) 851-891.
5. G.J. Clark and C.J. Der, ras proto-oncogene activation in human malignancy, in: C.T. Garret and S. Sell (Eds.), Cellular Cancer Markers, Hummana, Totowa, NJ, 1995, pp. 17-52.
6. E. Sinn, W. Muller, P. Pattengale, I. Tepler, R. Wallace, P. Leder, Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo, Cell 49 (1987) 465-475.
7. R. Mangues, I. Seidman, A. Pellicer, J.W. Gordon, Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene, Oncogene 5 (1990) 1491-1497.
8. T.Y. Shih, A.G. Papageorge, P.E. Stokes, M.O. Weeks, E.M. Scolnick, Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus, Nature 287 (1980) 686-691.
9. P. Chardin, J.H. Camonis, N.W. Gale, L. van-Aelst, J. Schlessinger, M.H. Wigler, D. Bar-Sagi, Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2, Science 260 (1993) 1338-1343.
10. G. Bollag, F. McCormick, GTPase activating proteins, Semin. Cancer Biol. 3 (1992) 199-208.
11. J.B. Gibbs, A. Oliff, The potential of farnesyltransferase inhibitors as cancer therapeutics, Annu. Rev. Pharmacol. Toxicol. 37 (1997) 143-166.
12. A.D. Cox, C.J. Der, Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?, Biochim. Biophys. Acta 1333 (1997) F51-71.
13. M.C. Willingham, I. Pastan, T.Y. Shih, E.M. Scolnick, Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry, Cell 19 (1980) 1005-1014.
14. B.M. Willumsen, K. Norris, A.G. Papageorge, N.L. Hubbert, D.R. Lowy, Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus, EMBO J. 3 (1984) 2581-2585.
15. K. Kato, A.D. Cox, M.M. Hisaka, S.M. Graham, J.E. Buss, C.J. Der, Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity, Proc. Natl. Acad. Sci. USA 89 (1992) 6403-6407.
16. Y. Reiss, J.L. Goldstein, M.C. Seabra, P.J. Casey, M.S. Brown, Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides, Cell 62 (1990) 81-88.
17. J.B. Gibbs, D.L. Pompliano, S.D. Mosser, E. Rands, R.B. Lingham, S.B. Singh, E.M. Scolnick, N.B. Kohl, A. Oliff, Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo, J. Biol. Chem. 268 (1993) 7617-7620.
18. W.J. Chen, D.A. Andres, J.L. Goldstein, D.W. Russell, M.S. Brown, cDNA cloning and expression of the peptide-binding beta subunit of rat p21ras farnesyltransferase, the counterpart of yeast DPR1/RAM1, Cell 66 (1991) 327-341.
19. C.A. Omer, A.M. Kral, R.E. Diehl, G.C. Prendergast, S. Powers, C.M. Allen, J.B. Gibbs, N.E. Kohl, Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases, Biochemistry 32 (1993) 5167-5176.
20. S.L. Moores, M.D. Schaber, S.D. Mosser, E. Rands, M.B. O'Hara, V.M. Garsky, M.S. Marshall, D.L. Pompliano, J.B. Gibbs, Sequence dependence of protein isoprenylation, J. Biol. Chem. 266 (1991) 14603-14610.
21. G. James, J.L. Goldstein, M.S. Brown, Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells, Proc. Natl. Acad. Sci. USA 93 (1996) 4454-4458.
22. D.B. Whyte, P. Kirschmeier, T.N. Hockenberry, I. Nunez-Oliva, L. James, J.J. Catino, W.R. Bishop, J.K. Pai, K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors, J. Biol. Chem. 30 (1997) 14459-14464.
23. F.L. Zhang, P. Kirschmeier, D. Carr, L. James, R.W. Bond, L. Wang, R. Patton, W.T. Windsor, R. Syto, R. Zhang, W.R. Bishop, Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I, J. Biol. Chem. 272 (1997) 10232-10239.
24. J. Sun, Y. Qian, A.D. Hamilton, S.M. Sebti, Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts, Oncogene 16 (1998) 1467-1473.
25. A.D. Cox, M.M. Hisaka, J.E. Buss, C.J. Der, Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein, Mol. Cell Biol. 12 (1992) 2606-2615.
26. K.S. Koblan and N.E. Kohl, Farnesyltransferase inhibitors: agents for the treatment of human cancer, in: G Proteins, Cytoskeleton and Cancer, R.G. Landes, 1998.
27. O. Kainuma, T. Asano, M. Hasegawa, T. Kenmochi, T. Nakagohri, Y. Tokoro, K. Isono, Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin, Pancreas 15 (1997) 379-383.
28. R.B. Lingham, K.C. Silverman, G.F. Bills, C. Cascales, M. Sanchez, R.G. Jenkins, S.E. Gartner, I. Martin, M.T. Diez, F. Pelaez, Chaetomella acutiseta produces chaetomellic acids A and B which are reversible inhibitors of farnesyl-protein transferase, Appl. Microbiol. Biotechnol. 40 (1993) 370-374.
29. M. Yonemoto, T. Satoh, H. Arakawa, I. Suzuki-Takahashi, Y. Monden, T. Kodera, K. Tanaka, T. Aoyama, Y. Iwasawa, T. Kamei, S. Nishimura, K. Tomimoto, J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner, Mol. Pharmacol. 54 (1998) 1-7.
30. D.J. Augeri, S.J. O'Connor, D. Janowick, B. Szczepankiewicz, G. Sullivan, J. Larsen, D. Kalvin, J. Cohen, E. Devine, H. Zhang, S. Cherian, B. Saeed, S.-C. Ng, S. Rosenberg, Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase, J. Med. Chem. 41 (1998) 4288-4300.
31. W.R. Bishop, R. Bond, J. Petrin, L. Wang, R. Patton, R. Doll, G. Njoroge, J. Catino, J. Schwartz, W. Windsor et al., Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells, J. Biol. Chem. 270 (1995) 30611-30618.
32. S.L. Graham, S.J. deSolms, E.A. Giuliani, N.E. Kohl, S.D. Mosser, A. Oliff, D.L. Pompliano, E. Rands, M.J. Breslin, A.A. Deana, V.M. Garsky, T.H. Scholz, J.B. Gibbs, R.L. Smith, Pseudopeptide inhibitors of Ras farnesyl-protein transferase, J. Med. Chem. 37 (1994) 725-732.
33. T.M. Williams, T.M. Ciccarone, S.C. MacTough, R.L. Bock, M.W. Conner, J.P. Davide, K. Hamilton, K.S. Koblan, N.E. Kohl, A.M. Kral, S.D. Mosser, C.A. Omer, D.L. Pompliano, E. Rands, M.D. Schaber, D. Shah, F.R. Wilson, J.B. Gibbs, S.L. Graham, G.D. Hartman, A. Oliff, R.L. Smith, 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non-carboxylic acid inhibitors of farnesyltransferase, J. Med. Chem. 39 (1996) 1345-1348.
34. S.J. deSolms, E.A. Giuliani, S.L. Graham, K.S. Koblan, N.E. Kohl, S.D. Mosser, A.I. Oliff, D.L. Pompliano, E. Rands, T.H. Scholz, C.M. Wiscount, J.B. Gibbs, R.L. Smith, N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase, J. Med. Chem. 41 (1998) 2651-2656.
35. K.S. Koblan, J.C. Culberson, S.J. Desolms, E.A. Giuliani, S.D. Mosser, C.A. Omer, S.M. Pitzenberger, M.J. Bogusky, NMR studies of novel inhibitors bound to farnesyl-protein transferase, Protein Sci. 4 (1995) 681-688.
36. H.W. Park, S.R. Boduluri, J.F. Moomaw, P.J. Casey, L.S. Beese, Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution, Science 275 (1997) 1800-1804.
37. P. Dunten, U. Kammlott, R. Crowther, D. Weber, R. Palermo, J. Birktoft, Protein farnesyltransferase: structure and implications for substrate binding, Biochemistry. 37 (1998) 7907-7912.
38. S.B. Long, P.J. Casey, L.S. Beese, Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate, Biochemistry. 37 (1998) 9612-9618.
39. N.E. Kohl, S.D. Mosser, S.J. deSolms, E.A. Guilian, S.L. Graham, R.L. Smith, E.M. Scolnick, A. Oliff, J.B. Gibbs, Selective inhibition of ras-dependent cell transformation by a farnesyl-protein transferase inhibitor, Science 260 (1993) 1934-1937.
40. G.L. James, J.L. Goldstein, M.S. Brown, T.E. Rawson, T.C. Somers, R.S. McDowell, C.W. Crowley, B.K. Lucas, A.D. Levinson, J.C. Marsters Jr., Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells, Science. 260 (1993) 1937-1942.
41. A.D. Cox, A.M. Garcia, J.K. Westwick, J.J. Kowalczyk, M.D. Lewis, D.A. Brenner, C.J. Der, The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation, J. Biol. Chem. 269 (1994) 19203-19206.
42. G.C. Prendergast, J.P. Davide, S.J. deSolms, E.A. Giuliani, S.L. Graham, J.B. Gibbs, A. Oliff, N.E. Kohl, Farnesyl transferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton, Mol. Cell. Biol. 14 (1994) 4193-4202.
43. P.F. Lebowitz, J.P. Davide, G.C. Prendergast, Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity, Mol. Cell Biol. 15 (1995) 6613-6622.
44. L. Sepp-Lorenzino, Z. Ma, E. Rands, N.E. Kohl, J.B. Gibbs, A. Oliff, N. Rosen, A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines, Cancer Res. 55 (1995) 5302-5309.
45. K. Miquel, A. Pradines, J. Sun, Y. Qian, A.D. Hamilton, S.M. Sebti, G. Favre, GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells, Cancer Res. 57 (1997) 1846-1850.
46. L. Sepp-Lorenzino, N. Rosen, A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells, J. Biol. Chem. 273 (1998) 20243-20251.
47. P.F. Lebowitz, D. Sakamuro, G.C. Prendergast, Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment, Cancer Res. 57 (1997) 708-713.
48. O. Kainuma, T. Asano, M. Hasegawa, K. Isono, Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor, Gan To Kagaku Ryoho. 23 (1996) 1657-1659.
49. H. Ura, T. Obara, R. Shudo, A. Itoh, S. Tanno, T. Fujii, N. Nishino, Y. Kohgo, Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts, Mol. Carcinog. 21 (1998) 93-99.
50. N.E. Kohl, F.R. Wilson, S.D. Mosser, E. Giuliani, S.J. deSolms, N.J. Anthony, W.J. Holtz, R.P. Gomez, T.-J. Lee, S.L. Graham, R.L. Smith, J.B. Gibbs, A. Oliff, Selective inhibition of ras-dependent tumors in nude mice by an inhibitor of farnesyltransferase, Proc. Natl. Acad. Sci. USA 91 (1994) 9141-9145.
51. M. Liu, M.S. Bryant, J. Chen, S. Lee, B. Yaremko, P. Lipari, M. Malkowski, E. Ferrari, L. Nielsen, N. Prioli et al., Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice, Cancer Res. 58 (1998) 4947-4956.
52. N.E. Kohl, C.A. Omer, M.W. Conner, N.J. Anthony, J.P. Davide, S.J. DeSolms, E.A. Giuliani, R.P. Gomez, S.L. Graham et al., Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in Ras transgenic mice, Nat. Med. 1 (1995) 792-797.
53. R. Mangues, T. Corral, N.E. Kohl, W.F. Symmans, S. Lu, M. Malumbres, J.B. Gibbs, A. Oliff, A. Pellicer, Antitumor Effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice, Cancer Res. 58 (1998) 1253-1259.
54. R.E. Barrington, M.A. Subler, E. Rands, C.A. Omer, P.J. Miller, I.E. Hundley et al., A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis, Mol. Cell Biol. 18 (1998) 85-92.
55. P.F. Lebowitz, P.J. Casey, G.C. Prendergast, J.A. Thissen, Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB, J. Biol. Chem. 272 (1997) 15591-15594.
56. E.C. Lerner, Y. Qian, M.A. Blaskovich, R.D. Fossum, A. Vogt, J. Sun, A.D. Cox, C.J. Der, A.D. Hamilton, S.M. Sebti, Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes, J. Biol. Chem. 270 (1995) 26802-26806.
57. A. Goga, J. McLaughlin, D.E. Afar, D.C. Saffran, O.N. Witte, Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene, Cell 82 (1995) 981-988.
58. L. Puil, J. Liu, G. Gish, G. Mbamalu, D. Bowtell, P.G. Pelicci, R. Arlinghaus, T. Pawson, Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway, EMBO J. 13 (1994) 764-773.
59. M.M. Moasser, L. Sepp-Lorenzino, N.E. Kohl, A. Oliff, A. Balog, D.-S. Su, S.J. Danishefsky, N. Rosen, Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones, Proc. Natl. Acad. Sci. USA 95 (1998) 1369-1374.
60. E.J. Bernhard, G. Kao, A.D. Cox, S.M. Sebti, A.D. Hamilton, R.J. Muschel, W.G. McKenna, The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts, Cancer Res. 56 (1996) 1727-1730.
61. E.J. Bernhard, W.G. McKenna, A.D. Hamilton, S.M. Sebti, Y. Qian, J.M. Wu, R.J. Muschel, Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes, Cancer Res. 58 (1998) 1754-1761.
62. F.G. Njoroge, A. Taveras, J. Kelly, S. Reminszewski, A.K. Mallams, R.J. Doll et al., Oral active, trihalobenzocycloheptapyridine farnesyl protein transferase inhibitor antitumor agents, Proceedings of the American Association for Cancer Research, 89th annual meeting 39:318, March 1998.
63. I.D. Horak, p21 Ras: a new target for therapeutic intervention, Proceedings of the 3rd International Symposium on Cancer Chemotherapy, December 1998, pp. 22-23.